Stanford is one of four institutions to receive National Cancer Institute funding to analyze patients’ immune function and tumor profiles as part of a public-private partnership to accelerate cancer therapies.
October 27, 2017
The School of Medicine is one of four institutions to receive a grant from the National Cancer Institute to establish a Center for the Immune Monitoring and Analysis of Cancer. Together, the centers will form a network of laboratories to support adult and pediatric immunotherapy trials by analyzing patients’ immune phenotype and function and performing deep tumor profiling.
The grant provides the Stanford center approximately $12.5 million over five years. It will be headed by Holden Maecker, PhD, professor of microbiology and immunology, and director of the Stanford Human Immune Monitoring Center; and Sean Bendall, PhD, assistant professor of pathology.
Other recipients of the CIMAC grants are the Dana-Farber Cancer Institute, the Icahn School of Medicine at Mount Sinai and the MD Anderson Cancer Center at the University of Texas.
The grants were announced by the National Cancer Institute as part of its $215 million Partnership for Accelerating Cancer Therapies effort, which is a public-private collaboration between the National Institutes of Health and 11 biopharmaceutical companies. The partnership is part of the NIH’s Cancer Moonshot.
Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford School of Medicine, Stanford Health Care, and Stanford Children's Health. For more information, please visit the Office of Communications website at http://mednews.stanford.edu.